ECSP034624A - Combinacion de agonista de gava e inhibidores de sorbitol-deshidrogenasa - Google Patents
Combinacion de agonista de gava e inhibidores de sorbitol-deshidrogenasaInfo
- Publication number
- ECSP034624A ECSP034624A EC2003004624A ECSP034624A ECSP034624A EC SP034624 A ECSP034624 A EC SP034624A EC 2003004624 A EC2003004624 A EC 2003004624A EC SP034624 A ECSP034624 A EC SP034624A EC SP034624 A ECSP034624 A EC SP034624A
- Authority
- EC
- Ecuador
- Prior art keywords
- pro
- drug
- agonist
- sdi
- combinations
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 229940002612 prodrug Drugs 0.000 abstract 6
- 239000000651 prodrug Substances 0.000 abstract 6
- 239000003477 4 aminobutyric acid receptor stimulating agent Substances 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 206010007749 Cataract diabetic Diseases 0.000 abstract 1
- 208000002249 Diabetes Complications Diseases 0.000 abstract 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 abstract 1
- 208000032781 Diabetic cardiomyopathy Diseases 0.000 abstract 1
- 208000008960 Diabetic foot Diseases 0.000 abstract 1
- 206010054044 Diabetic microangiopathy Diseases 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 201000009101 diabetic angiopathy Diseases 0.000 abstract 1
- 201000007025 diabetic cataract Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Esta invención se refiere a composiciones farmacéuticas que comprenden combinaciones de un agonista GABA, un pro fármaco del mismo o una sal farmacéutica mente aceptable de dicho agonista de GABA o dicho pro fármaco y un SDI, un pro fármaco del mismo, o una sal farmacéuticamente aceptable de dicho agonista de GABA o dicho pro fármaco y un SDI, un pro fármaco del mismos o una sal farmacéutica mente aceptable de dicho SDI o dicho pro fármaco, estuches que contienen tales combinaciones y métodos para utilizar tales combinaciones en el tratamiento de mamíferos, incluidos los seres humanos que padecen complicaciones de la diabetes tales como neuropatía diabética, cardiomiopatía diabética, retinopatía diabética, microangiopatia diabética, cataratas o úlceras de los pies.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25006900P | 2000-11-30 | 2000-11-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP034624A true ECSP034624A (es) | 2003-07-25 |
Family
ID=22946187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2003004624A ECSP034624A (es) | 2000-11-30 | 2003-05-27 | Combinacion de agonista de gava e inhibidores de sorbitol-deshidrogenasa |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US6544998B2 (es) |
| EP (1) | EP1337271B1 (es) |
| JP (1) | JP2004514699A (es) |
| KR (1) | KR20030059290A (es) |
| CN (1) | CN1477975A (es) |
| AP (1) | AP2001002360A0 (es) |
| AR (1) | AR031431A1 (es) |
| AT (1) | ATE281181T1 (es) |
| AU (1) | AU2002215159A1 (es) |
| BG (1) | BG107774A (es) |
| BR (1) | BR0115783A (es) |
| CA (1) | CA2430298A1 (es) |
| CR (1) | CR6964A (es) |
| CZ (1) | CZ20031399A3 (es) |
| DE (1) | DE60106968T2 (es) |
| DO (1) | DOP2001000289A (es) |
| EA (1) | EA200300432A1 (es) |
| EC (1) | ECSP034624A (es) |
| EE (1) | EE200300248A (es) |
| ES (1) | ES2230378T3 (es) |
| HR (1) | HRP20030420A2 (es) |
| HU (1) | HUP0302160A3 (es) |
| IL (1) | IL155704A0 (es) |
| IS (1) | IS6786A (es) |
| MA (1) | MA26964A1 (es) |
| MX (1) | MXPA03004870A (es) |
| NO (1) | NO20032441L (es) |
| OA (1) | OA12534A (es) |
| PA (1) | PA8534101A1 (es) |
| PE (1) | PE20020597A1 (es) |
| PL (1) | PL365927A1 (es) |
| PT (1) | PT1337271E (es) |
| SK (1) | SK6192003A3 (es) |
| SV (1) | SV2003000751A (es) |
| TN (1) | TNSN01169A1 (es) |
| UY (1) | UY27042A1 (es) |
| WO (1) | WO2002043762A2 (es) |
| ZA (1) | ZA200303381B (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL189872B1 (pl) | 1996-07-24 | 2005-10-31 | Warner Lambert Co | Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu |
| US6992109B1 (en) * | 1999-04-08 | 2006-01-31 | Segal Catherine A | Method for the treatment of incontinence |
| US7022678B2 (en) * | 2001-03-30 | 2006-04-04 | Warner-Lambert Company | Pregabalin lactose conjugates |
| DE60213592T2 (de) | 2001-05-25 | 2007-08-09 | Warner-Lambert Co. Llc | Flüssige pharmazeutische zusammensetzung |
| CA2451267A1 (en) * | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
| KR20050036195A (ko) * | 2003-10-15 | 2005-04-20 | 고재영 | 신규한 망막병증 치료제 조성물 |
| US20050220873A1 (en) * | 2004-04-02 | 2005-10-06 | Chien-Hsuan Han | Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist |
| US20050226927A1 (en) * | 2004-04-02 | 2005-10-13 | Impax Laboratories, Inc. | Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist |
| JP2007531727A (ja) * | 2004-04-02 | 2007-11-08 | インパックス ラボラトリーズ インコーポレーティッド | Ｇａｂａｂ受容体アゴニストを含有する即時放出特性および／または制御放出特性を有する薬学的剤形 |
| US8007827B2 (en) * | 2004-04-02 | 2011-08-30 | Impax Laboratories, Inc. | Pharmaceutical dosage forms having immediate release and/or controlled release properties |
| GB0420831D0 (en) | 2004-09-17 | 2004-10-20 | Glaxo Group Ltd | Novel compounds |
| TWI385164B (zh) | 2005-02-17 | 2013-02-11 | Astellas Pharma Inc | Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate derivatives (II) |
| GB0513553D0 (en) * | 2005-07-01 | 2005-08-10 | Fond D Amico Per La Ricerca Su | Rab3a |
| CA2685266C (en) * | 2007-04-27 | 2014-01-28 | Purdue Pharma L.P. | Trpv1 antagonists and uses thereof for the treatment of prevention of pain, ui and ulcer, ibd, or ibs in an animal |
| ES2416723T3 (es) * | 2007-10-09 | 2013-08-02 | Merck Patent Gmbh | Composiciones farmacéuticas que contienen benfotiamina y gabapentina |
| SG157299A1 (en) | 2008-05-09 | 2009-12-29 | Agency Science Tech & Res | Diagnosis and treatment of kawasaki disease |
| ES2758554T3 (es) | 2009-12-08 | 2020-05-05 | Univ Case Western Reserve | Aminoácidos gama para tratamiento de trastornos oculares |
| DK2621282T3 (da) * | 2010-09-28 | 2020-05-04 | Univ California | Gaba-agonister i behandlingen af forstyrrelser forbundet med metabolisk syndrom og gaba-kombinationer i behandling eller profylakse af type i diabetes |
| PE20141531A1 (es) | 2011-06-22 | 2014-10-23 | Purdue Pharma Lp | Antagonistas de trpv1 que incluyen sustituyentes dihidroxi y sus usos |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| US12377112B2 (en) | 2019-04-17 | 2025-08-05 | Compass Pathfinder Limited | Methods of treating neurocognitive disorders, chronic pain and reducing inflammation |
| JP2022531466A (ja) * | 2019-05-07 | 2022-07-06 | ユニバーシティ オブ マイアミ | 遺伝性ニューロパチーおよび関連障害の処置および検出 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2409754A (en) | 1946-10-22 | Method for obtaining hydantoins | ||
| CH449645A (de) | 1963-07-09 | 1968-01-15 | Ciba Geigy | Verfahren zur Herstellung neuer Aminosäuren |
| CH427803A (de) | 1963-12-06 | 1967-01-15 | Geigy Ag J R | Verfahren zur Herstellung eines neuen Isoxazolderivates |
| DE2460891C2 (de) * | 1974-12-21 | 1982-09-23 | Gödecke AG, 1000 Berlin | 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| US3960927A (en) | 1975-03-18 | 1976-06-01 | Richardson-Merrell Inc. | Olefinic derivatives of amino acids |
| FR2319338A1 (fr) * | 1975-08-01 | 1977-02-25 | Synthelabo | Nouveaux derives de a- phenyl benzylideniques des acides amines, leur preparation et les medicaments qui en contiennent |
| DK153787C (da) | 1979-06-01 | 1989-01-16 | Wellcome Found | Analogifremgangsmaade til fremstilling af substituerede 3,5-diamino-6-phenyl-1,2,4-triaziner og alfa-cyanobenzyliden-aminoguanidinforbindelser til anvendelse som mellemprodukter herved |
| FR2492258A1 (fr) * | 1980-10-17 | 1982-04-23 | Pharmindustrie | Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole |
| US4513006A (en) | 1983-09-26 | 1985-04-23 | Mcneil Lab., Inc. | Anticonvulsant sulfamate derivatives |
| DK288385D0 (da) | 1985-06-26 | 1985-06-26 | Novo Industri As | Aminosyrederivater |
| US6197819B1 (en) | 1990-11-27 | 2001-03-06 | Northwestern University | Gamma amino butyric acid analogs and optical isomers |
| US5728704A (en) * | 1992-09-28 | 1998-03-17 | Pfizer Inc. | Substituted pyridmidines for control of diabetic complications |
| US6350769B1 (en) * | 1999-02-24 | 2002-02-26 | The Regents Of The University Of California | Gaba alpha receptors mediate inhibition of T cell responses |
| PL350884A1 (en) * | 1999-04-01 | 2003-02-10 | Pfizer Prod Inc | Aminopyrimidines as sorbitol dehydrogenase inhibitors |
| PT1041068E (pt) * | 1999-04-01 | 2004-07-30 | Pfizer Prod Inc | Compostos para o tratamento e prevencao de complicacoes diabeticas |
-
2001
- 2001-11-19 CA CA002430298A patent/CA2430298A1/en not_active Abandoned
- 2001-11-19 IL IL15570401A patent/IL155704A0/xx unknown
- 2001-11-19 OA OA1200300142A patent/OA12534A/en unknown
- 2001-11-19 DE DE60106968T patent/DE60106968T2/de not_active Expired - Fee Related
- 2001-11-19 SK SK619-2003A patent/SK6192003A3/sk unknown
- 2001-11-19 WO PCT/IB2001/002213 patent/WO2002043762A2/en not_active Ceased
- 2001-11-19 DO DO2001000289A patent/DOP2001000289A/es unknown
- 2001-11-19 HR HR20030420A patent/HRP20030420A2/hr not_active Application Discontinuation
- 2001-11-19 AU AU2002215159A patent/AU2002215159A1/en not_active Abandoned
- 2001-11-19 PL PL01365927A patent/PL365927A1/xx not_active Application Discontinuation
- 2001-11-19 AP APAP/P/2001/002360A patent/AP2001002360A0/en unknown
- 2001-11-19 ES ES01983739T patent/ES2230378T3/es not_active Expired - Lifetime
- 2001-11-19 BR BR0115783-3A patent/BR0115783A/pt not_active IP Right Cessation
- 2001-11-19 PT PT01983739T patent/PT1337271E/pt unknown
- 2001-11-19 JP JP2002545732A patent/JP2004514699A/ja not_active Withdrawn
- 2001-11-19 MX MXPA03004870A patent/MXPA03004870A/es unknown
- 2001-11-19 HU HU0302160A patent/HUP0302160A3/hu unknown
- 2001-11-19 EE EEP200300248A patent/EE200300248A/xx unknown
- 2001-11-19 CZ CZ20031399A patent/CZ20031399A3/cs unknown
- 2001-11-19 KR KR10-2003-7007237A patent/KR20030059290A/ko not_active Ceased
- 2001-11-19 CN CNA018195946A patent/CN1477975A/zh active Pending
- 2001-11-19 EP EP01983739A patent/EP1337271B1/en not_active Expired - Lifetime
- 2001-11-19 EA EA200300432A patent/EA200300432A1/ru unknown
- 2001-11-19 AT AT01983739T patent/ATE281181T1/de not_active IP Right Cessation
- 2001-11-27 UY UY27042A patent/UY27042A1/es not_active Application Discontinuation
- 2001-11-28 AR ARP010105541A patent/AR031431A1/es unknown
- 2001-11-28 PE PE2001001191A patent/PE20020597A1/es not_active Application Discontinuation
- 2001-11-29 US US09/997,038 patent/US6544998B2/en not_active Expired - Fee Related
- 2001-11-29 SV SV2001000751A patent/SV2003000751A/es unknown
- 2001-11-29 TN TNTNSN01169A patent/TNSN01169A1/fr unknown
- 2001-11-30 PA PA20018534101A patent/PA8534101A1/es unknown
-
2003
- 2003-04-14 IS IS6786A patent/IS6786A/is unknown
- 2003-04-24 CR CR6964A patent/CR6964A/es not_active Application Discontinuation
- 2003-04-30 ZA ZA200303381A patent/ZA200303381B/en unknown
- 2003-05-07 BG BG107774A patent/BG107774A/xx unknown
- 2003-05-20 MA MA27165A patent/MA26964A1/fr unknown
- 2003-05-27 EC EC2003004624A patent/ECSP034624A/es unknown
- 2003-05-28 NO NO20032441A patent/NO20032441L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP034624A (es) | Combinacion de agonista de gava e inhibidores de sorbitol-deshidrogenasa | |
| DOP2001000294A (es) | Combinación de agonistas de gaba e inhibidores de aldosa-reductasa | |
| AR067347A1 (es) | Combinacion antihelmintica | |
| MX2021008358A (es) | Lipidos para la administracion de agentes activos en nanoparticulas lipidicas. | |
| AR067903A1 (es) | Metodo para tratar la depresion mediada por estres | |
| PA8615301A1 (es) | Formulaciones farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y prevencion de sindromes coronarios agudos. | |
| CO6331425A2 (es) | Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida | |
| AR053651A1 (es) | Tratamiento combinado de anticuerpo antictla4 r inhibidor de aromatasa para el cancer de mama | |
| AR026610A1 (es) | Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central | |
| MX2009001659A (es) | Compuestos de 2,5-dihidroxibenceno para el tratamiento de rosacea. | |
| UY28231A1 (es) | Metodos y composiciones farmacéuticas para la obtención confiable de niveles aceptables de testosterona en suero. | |
| CY1112269T1 (el) | Συνθεσεις και μεθοδοι για την αγωγη, μειωση, βελτιωση, ή ανακουφιση των οφθαλμικων παθησεων οπισθιου- τμηματος | |
| CL2008003576A1 (es) | Compuestos derivados de amida del acido 6,7-dihidro-5h-imidazo[1,2-alfa]imidazol-3-carboxilico; composicion farmaceutica que los comprende; y usos en el tratamiento de una afeccion inflamatoria. | |
| GT200600163A (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion | |
| PA8515601A1 (es) | El uso de composiciones a base de antibioticos de azalidos para tratar o prevenir una infeccion bacteriana o protozoaria en mamiferos | |
| AR128464A1 (es) | Péptidos agonistas duales glp-1 y glucagón con estabilidad biológica mejorada | |
| CL2025000581A1 (es) | Estructuras derivadas de tn3 específicas de cd40l; tratamiento, prevención del síndrome de sjögren | |
| CO2022001218A2 (es) | Composición de inhibidor micromolecular de pi4kiiiα, método de preparación y uso | |
| AR055628A1 (es) | Dipositivos de administracion transdermicas de farmacos que contienen o- desmetilvenlafaxina (odv) o sus sales | |
| CY1114480T1 (el) | Συνθεσεις που περιλαμβανουν διαχωρισμενο αγωνιστη υποδοχεα γλυκοκορτικοειδους για τη θεραπεια ή τον ελεγχο φλεγμονης προσθιου τμηματος | |
| AR047726A1 (es) | Metodos y reactivos para el tratamiento de trastornos inflamatorios | |
| MXPA05013104A (es) | Metodo para el tratamiento o prevencion de sintomas del tracto urinario inferior. | |
| AR043016A2 (es) | Un compuesto antimigranico eletriptan y composicion farmaceutica que lo contiene | |
| PE20020907A1 (es) | Combinacion de taxano y una cinasa dependiente de la ciclina | |
| AR046213A1 (es) | Forma de presentacion del naproxeno sodico |